Novartis AG ADR
$ 139.18
0.22%
26 Dec - close price
- Market Cap 267,057,463,000 USD
- Current Price $ 139.18
- High / Low $ 139.22 / 138.39
- Stock P/E 19.04
- Book Value 23.10
- EPS 7.31
- Next Earning Report 2026-01-30
- Dividend Per Share $3.86
- Dividend Yield 2.87 %
- Next Dividend Date -
- ROA 0.12 %
- ROE 0.33 %
- 52 Week High 140.18
- 52 Week Low 93.54
About
Novartis AG (ADR), headquartered in Basel, Switzerland, is a leading global healthcare company focused on the research, development, manufacturing, and commercialization of innovative pharmaceuticals and medical devices. With a diverse portfolio of patented therapies in key therapeutic areas including oncology, cardiology, and immunology, Novartis employs cutting-edge science to deliver improved patient outcomes. The firm's commitment to robust research and development, combined with strategic collaborations, solidifies its position at the forefront of the evolving healthcare landscape, making it an attractive option for institutional investors interested in the pharmaceutical sector.
Analyst Target Price
$134.88
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-07-17 | 2025-04-29 | 2025-01-30 | 2024-10-28 | 2024-07-17 | 2024-04-22 | 2024-01-30 | 2023-10-24 | 2023-07-17 | 2023-04-25 | 2023-01-31 |
| Reported EPS | 2.25 | 2.42 | 2.28 | 1.98 | 2.06 | 1.97 | 1.8 | 1.53 | 1.74 | 1.83 | 1.71 | 1.52 |
| Estimated EPS | 2.31 | 2.37 | 2.17 | 1.76 | 1.93 | 1.86 | 1.68 | 1.66 | 1.74 | 1.76 | 1.53 | 1.43 |
| Surprise | -0.06 | 0.05 | 0.11 | 0.22 | 0.13 | 0.11 | 0.12 | -0.13 | 0 | 0.07 | 0.18 | 0.09 |
| Surprise Percentage | -2.5974% | 2.1097% | 5.0691% | 12.5% | 6.7358% | 5.914% | 7.1429% | -7.8313% | 0% | 3.9773% | 11.7647% | 6.2937% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-01-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.97 |
| Currency | USD |
Previous Dividend Records
| Apr 2025 | Apr 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-04-25 | 2024-04-19 | 2023-03-20 | 2022-03-17 | 2021-03-15 | None | None | None | None | None |
| Amount | $3.99399 | $3.7395445 | $3.4693612 | $3.3574492 | $3.3783783 | $3.0424917 | $2.865 | $2.977 | $2.717759 | $2.717946 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVS
2025-12-27 12:09:00
Greenup Street Wealth Management LLC recently reduced its stake in Novartis AG (NYSE:NVS) by 25.7% during the third quarter, selling 10,775 shares and retaining 31,232 shares valued at $4.005 million. Despite this trimming, other institutional investors have either increased or initiated positions in Novartis. Novartis holds a "Hold" consensus rating from analysts with an average price target of $119.75, and its recent Q3 earnings showed revenue beating estimates while EPS slightly missed.
2025-12-26 14:09:05
Voya Investment Management LLC significantly reduced its stake in Novartis AG (NYSE:NVS) by 23.0% in Q3, selling 9,940 shares and retaining 33,285 shares valued at $4.27 million. Despite this, Novartis's stock is trading near its 52-week high, with a market capitalization of approximately $291.6 billion, and the company reported strong Q3 revenue that exceeded expectations. While analysts have mixed views, with recent upgrades from Bank of America and Morgan Stanley, the consensus remains a "Hold" rating with a target price of $119.75.
2025-12-26 09:09:05
DAVENPORT & Co LLC increased its holdings in Novartis AG by 24.8% in Q3, purchasing 8,353 shares to own a total of 42,036 shares valued at approximately $5.39 million. Novartis posted a slight EPS miss but exceeded revenue expectations with $14.36 billion. The stock currently has a "Hold" rating from analysts with a target price of $119.75, though some firms recently upgraded it.
2025-12-24 13:09:20
A new report from Coherent Market Insights projects strong growth for the Ocular Implant Market from 2025 to 2032, driven by increasing demand, expanding applications, and technological advancements. The study provides an overview of market size, revenue trends, and key growth factors, alongside a competitive analysis of major industry players like Novartis AG, Pfizer Inc., and Johnson & Johnson Services. It also highlights segmentation by implant type and application, offering actionable insights for strategic decision-making in the global market.
2025-12-24 07:09:20
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novartis AG (NOVN) with the company's shares closing at CHF110.10. Deutsche Bank also reiterated a Buy rating with a CHF120.00 price target. Novartis reported quarterly revenue of CHF14.36 billion and a net profit of CHF3.93 billion, showing growth compared to the previous year.
2025-12-21 10:09:41
Texas Permanent School Fund Corp reduced its stake in Novartis AG (NYSE:NVS) by 31.0% in Q2, selling 9,317 shares and retaining 20,764 shares valued at $2.51 million. Novartis recently entered a formal agreement with the U.S. government to lower drug prices, which impacts U.S. revenue and margins, leading to trimmed near-term EPS estimates. Despite mixed analyst ratings and the stock trading near its 52-week high, Novartis has also announced positive developments such as orphan drug designation for a myasthenia gravis treatment and a proposed $280 million investment in Denton for life-sciences manufacturing expansion.
